Home › NDC Lookup › Ingredients › Topiramate › 65841-0647-01
topiramate 25 mg Tablet, Film Coated, 100-count — NDC 65841-0647-01 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

topiramate 25 mg Tablet, Film Coated, 100-count — NDC 65841-647-01 (Billing 65841-0647-01)

by Zydus Lifesciences Limited · 100 TABLET, FILM COATED in 1 BOTTLE

This is a package of 100 tablets of topiramate 25 mg Tablet, Film Coated from Zydus Lifesciences Limited, marketed since Mar 2009 and currently FDA-listed. It is the main listing for this product, which comes in 4 package sizes.

NDC 65841-0647-01
🏷️ FDA NDC (as labeled) 65841-647-01 billing pads the product segment with a zero
This package
Contains100-count Pack sizes4 compare ↓
Also priced by: Part D plans $0.0808/unit — full pricing hub ↓
Main listing for product 65841-647 · Also comes in: 60 tablets 65841-647-14 90 tablets 65841-647-16 500 tablets 65841-647-05
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 65841-647-01
Product NDC 65841-647
11-digit billing NDC 65841064701
RxCUI 151226, 199888, 199889, 199890
UNII 0H73WJJ391
UPC 0368382141149, 0368382139146
Application # ANDA078235
SPL Set ID 57016639-89fe-43ad-89c4-5e7a756dddec
Mechanism of action Cytochrome P450 3A4 Inducers; Cytochrome P450 2C19 Inhibitors
Physiologic effect Decreased Central Nervous System Disorganized Electrical Activity
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2009-03-27
Route ORAL
Dosage form TABLET, FILM COATED
Substance TOPIRAMATE
TE code (Orange Book) AB · RLD · RS
Quick answers
  • RxCUI (RxNorm): 151226
Why two NDCs? The FDA registers this code as 65841-647-01 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 65841-0647-01. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Centrally acting antiobesity products class.

Drug family (ATC) Centrally acting antiobesity products, Other antiepileptics
How it works Cytochrome P450 2C19 Inhibitors, Cytochrome P450 3A4 Inducers
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

📖 What it is MedlinePlus · NLM

Topiramate is used to treat certain types of seizures. Topiramate is also used to prevent migraine headaches but not to relieve the pain of migraine headaches when they occur. Topiramate is in a class of medications called anticonvulsants. It works by decreasing abnormal excitement in the brain.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • It treats certain seizures in epilepsy, either alone or added to other medicines. Most products also prevent migraine in people 12 and older. Generic topiramate tablets are labeled...
  • Take it by mouth exactly as prescribed. Your doctor will raise the dose slowly. Trokendi XR must be swallowed whole, while Qudexy XR can be sprinkled on soft food. Don't stop sudde...
  • Tingling, dizziness, sleepiness, tiredness, appetite and weight loss, and trouble with memory, concentration or speech are common. Tell me if they bother you.
  • Call right away for eye pain or vision changes, decreased sweating with a fever, mood changes or suicidal thoughts, a severe rash, or confusion. These can be serious.
📖 Read our full Topiramate guide →
1
Nutrient depletion considerations

Topiramate may be associated with lower levels of 1 nutrient — worth a chat with your pharmacist, not a cause for alarm.

🧪 Full Topiramate nutrient depletion report →
An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eachPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · Q2 2026 $0.0808 $8.08 / 100 tablets
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
65841-0647-01 You're viewing this Main listing 100 TABLET, FILM COATED in 1 BOTTLE 2009-03-27 — Active
65841-0647-05 65841-647-05 500 TABLET, FILM COATED in 1 BOTTLE 2009-03-27 — Active
65841-0647-14 65841-647-14 60 TABLET, FILM COATED in 1 BOTTLE 2009-03-27 — Active
65841-0647-16 65841-647-16 90 TABLET, FILM COATED in 1 BOTTLE 2009-03-27 — Active

You're viewing one of 4 pack sizes for this product.

Pack size FAQ

What quantity is in this package?
This is a 100-count package — 100 tablet, film coated in 1 bottle.
How does this package differ from NDC 65841-0647-14?
Both are topiramate 25 mg Tablet, Film Coated — the drug itself is identical. This page's package is the 100-count one, while NDC 65841-0647-14 is the 60 tablets package.
What NDC number is used to bill for this package of topiramate 25 mg Tablet, Film Coated?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
topiramate 25 mg 00904-6928-61 Major 1 tablet $0.027 AB Availability likely —
Topiramate 25 mg 68084-0342-01 American 1 tablet $0.027 AB Availability likely —
Topiramate 25 mg 68462-0108-05 Glenmark 500 tablets $0.027 AB Availability likely —
Topiramate 25 mg 69097-0122-03 Cipla 60 tablets $0.027 AB Availability likely —
Topiramate 25 mg 76282-0278-10 EXELAN 1000 tablets $0.027 AB Availability likely —
topiramate 25 mg 82009-0135-05 Quallent 500 tablets $0.027 AB Availability likely —
Topiramate 25 mg 69097-0816-03 Cipla 60 tablets $0.035 AB FDA listed —
Topamax 25 mg 50458-0639-65 Janssen 60 tablets $6.578 AB Availability likely —
Topiramate 25 mg 00615-8138-39 NCS 30 tablets — AB Discontinued —
Topiramate 25 mg 00615-8593-39 NCS 30 tablets — AB FDA listed —
topiramate 25 mg 29300-0115-01 Unichem 100 tablets — AB FDA listed —
Topiramate 25 mg 31722-0181-05 Camber 500 tablets — AB FDA listed —
Topiramate 25 mg 43063-0735-15 PD-Rx 15 tablets — AB FDA listed —
Topiramate 25 mg 43063-0998-30 PD-Rx 30 tablets — AB FDA listed —
Topiramate 25 mg 47335-0707-08 Sun 100 tablets — AB FDA listed —
topiramate 25 mg 50090-2102-00 A-S 60 tablets — AB FDA listed —
Topiramate 25 mg 50090-4614-00 A-S 60 tablets — AB FDA listed —
topiramate 25 mg 50090-5853-00 A-S 60 tablets — AB FDA listed —
Topiramate 25 mg 50090-6827-00 A-S 90 tablets — AB FDA listed —
topiramate 25 mg 50090-7067-00 A-S 90 tablets — AB FDA listed —
topiramate 25 mg 50268-0806-15 AvPAK 1 tablet — AB FDA listed —
topiramate 25 mg 51655-0429-26 Northwind 90 tablets — AB FDA listed —
topiramate 25 mg 55154-7146-00 Cardinal 1 tablet — AB FDA listed —
topiramate 25 mg 60760-0075-30 St. 30 tablets — AB FDA listed —
topiramate 25 mg 60760-0752-60 St. 60 tablets — AB FDA listed —
Topiramate 25 mg 62756-0707-08 Sun 100 tablets — AB FDA listed —
Topiramate 25 mg 63187-0077-30 Proficient 30 tablets — AB FDA listed —
Topiramate 25 mg 63187-0118-30 Proficient 30 tablets — AB FDA listed —
Topiramate 25 mg 63187-0773-30 Proficient 30 tablets — AB FDA listed —
topiramate 25 mgthis 65841-0647-01 Zydus 100 tablets — AB FDA listed —
Topiramate 25 mg 65862-0171-05 Aurobindo 500 tablets — AB FDA listed —
topiramate 25 mg 67046-0375-03 Coupler 30 tablets — AB FDA listed —
topiramate 25 mg 67046-1180-03 Coupler 30 tablets — AB FDA listed —
Topiramate 25 mg 68071-1971-03 NuCare 30 tablets — AB FDA listed —
topiramate 25 mg 68071-3660-03 NuCare 30 tablets — AB FDA listed —
topiramate 25 mg 68382-0138-01 Zydus 100 tablets — AB FDA listed —
topiramate 25 mg 68788-7460-03 Preferred 30 tablets — AB FDA listed —
topiramate 25 mg 68788-8817-03 Preferred 30 tablets — AB FDA listed —
topiramate 25 mg 70518-0233-00 REMEDYREPACK 30 tablets — AB FDA listed —
Topiramate 25 mg 70518-0625-01 REMEDYREPACK 30 tablets — AB FDA listed —
topiramate 25 mg 70518-1718-01 REMEDYREPACK 1 tablet — AB FDA listed —
topiramate 25 mg 70518-4515-00 REMEDYREPACK 120 tablets — AB FDA listed —
topiramate 25 mg 71205-0202-30 Proficient 30 tablets — AB FDA listed —
Topiramate 25 mg 71205-0214-30 Proficient 30 tablets — AB FDA listed —
topiramate 25 mg 71205-0233-30 Proficient 30 tablets — AB FDA listed —
Topiramate 25 mg 71335-0548-00 Bryant 28 tablets — AB Discontinued —
topiramate 25 mg 71335-1684-00 Bryant 28 tablets — AB FDA listed —
topiramate 25 mg 71335-9727-00 Bryant 28 tablets — AB FDA listed —
Topiramate 25 mg 71610-0485-30 Aphena 30 tablets — AB FDA listed —
topiramate 25 mg 72162-2480-00 Bryant 1000 tablets — AB FDA listed —
Topiramate 25 mg 72789-0471-90 PD-Rx 90 tablets — AB FDA listed —
Topiramate 25 mg 72865-0313-10 XLCare 1000 tablets — AB FDA listed —
Topiramate 25 mg 76420-0278-30 Asclemed 30 tablets — AB FDA listed —
Topiramate 25 mg 80425-0208-02 Advanced 30 tablets — AB FDA listed —
Topiramate 25 mg 80425-0288-01 Advanced 30 tablets — AB FDA listed —
topiramate 25 mg 80425-0576-01 Advanced 30 tablets — AB FDA listed —
Topiramate 25 mg 87441-0079-01 Unit 30 tablets — AB FDA listed —
Topiramate 25 mg 70518-2517-00 REMEDYREPACK 30 tablets — AB Discontinued —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2009
On the market since
Mar 2009
📍
2026
Currently FDA-listed
17 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

What it looks like

Color White
ShapeRound
ImprintZD;13
Size12 mm
ScoringNot scored
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII 3SY5LH9PMK
    Anhydrous lactose is a milk sugar with no water content. It acts as a filler and binder in tablets and capsules, adding bulk and helping ingredients stick together.
  • UNII OP1R32D61U
    Microcrystalline cellulose is a purified form of cellulose, a natural fiber from plant sources. It acts as a binder and filler in tablets and capsules, helping hold ingredients together and give the medicine its shape and size.
  • UNII 3NXW29V3WO
    Hypromellose is a plant-based thickener made from cellulose. It's used in medicines as a binder to hold ingredients together, a coating for tablets, and a thickener for liquids.
  • UNII 70097M6I30
    Magnesium stearate is a salt made from magnesium and stearic acid, a fatty substance. It's used in tablets and capsules as a lubricant and glidant to help ingredients flow smoothly during manufacturing and prevent sticking.
  • UNII 3WJQ0SDW1A
    Polyethylene glycol is a synthetic liquid or solid polymer used in medicines as a solvent, lubricant, and humectant. It helps dissolve active ingredients, reduces friction during manufacturing, and retains moisture in the final product.
  • UNII ETJ7Z6XBU4
    Silicon dioxide is a naturally occurring mineral used as a glidant and anti-caking agent. It helps powder ingredients flow smoothly and prevents clumping during manufacturing and storage.
  • UNII 5856J3G2A2
    A starch-based powder made from potatoes and processed with sodium. It acts as a disintegrant, helping the tablet or capsule break apart quickly in the stomach so the medicine can be absorbed.
  • UNII 7SEV7J4R1U
    A powder made from a naturally occurring mineral. In medicines, talc works as a glidant and anti-caking agent, helping tablets and capsules flow smoothly during manufacturing and preventing clumping.
  • UNII 15FIX9V2JP
    Titanium dioxide is a bright white mineral powder commonly used as a colorant and opacifying agent. It makes pills and tablets white or lighter in color and helps make coatings non-transparent.

9 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerZydus Lifesciences Limited
Application holderZYDUS PHARMACEUTICALS USA INC
FDA applicationANDA078235 (ANDA)
Labeler code65841
First marketedMar 2009
Product typeHuman Prescription Drug
Portfolio717 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
💬 Medication Guide
💬 Medication Guide 2 words ▾

SPL MEDGUIDE

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Topiramate — the program that covers self-administered drugs. 17 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Topiramate. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$11.47M
Claims incl. refills
835.2K
Beneficiaries
482K
Spend / beneficiary
$23.80
Spend / claim
$13.73
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

About this NDC listing & data coverage

Finished prescription product
What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos ✓ Available
Inactive ingredients (structured) ✓ Available
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data ✓ Available
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Zydus Lifesciences Limited. Listing status can change — the directory data on this page refreshes weekly.
Does this product come in other package sizes?
Yes — the FDA directory lists 3 other package presentations of this same product, including 60 tablets (65841-0647-14), 90 tablets (65841-0647-16), 500 tablets (65841-0647-05). Each has its own NDC and its own page — see the package list near the top of this page.
Who lists this product with the FDA?
Zydus Lifesciences Limited is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
← 65841-0639-01 · Zydus 65841-0648-01 · Zydus →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.